Author details

Full Name

Divya Gupta

Affiliation

Emory University School of Medicine

ORCID

Career Start Year

2006

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37294913	Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy.	JCO Clin Cancer Inform	2023
37516286	Management and outcomes of heart transplant candidates with bloodstream infection on temporary mechanical circulatory support.	J Heart Lung Transplant	2023
37060236	Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.	Cancer	2023
37016186	Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance.	Oncol Ther	2023
37295725	Partial-Length Treatment With Brachytherapy in Patients With Endometrial Cancer With High-Risk Features Is as Effective as Full-Length Vaginal Brachytherapy but With Reduced Toxicity.	Pract Radiat Oncol	2023
34483300	Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence.	Int J Gynecol Pathol	2022
35550709	Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.	Gynecol Oncol	2022
35791804	Niraparib treatment for patients with <i>BRCA</i>-mutated ovarian cancer: review of clinical data and therapeutic context.	Future Oncol	2022
35690498	OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.	Gynecol Oncol	2022
36970052	<i>Ad hoc</i> Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline <i>BRCA</i> Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects.	Cancer Res Commun	2022
36102225	Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer.	Future Oncol	2022
36172173	Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.	Ther Adv Med Oncol	2022
34378405	Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in theÂ USA with ovarian cancer from 2011 to 2018.	Future Oncol	2021
32886901	Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.	J Natl Compr Canc Netw	2020
31562799	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.	N Engl J Med	2019
27910064	Clinical Behavior and Treatment of Endometrial Cancer.	Adv Exp Med Biol	2017
26896827	Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes.	Gynecol Oncol	2016
26942126	Disparities in Gynecological Malignancies.	Front Oncol	2016
26986692	Does the Presence of Endometriosis Affect Prognosis of Ovarian Cancer?	Cancer Invest	2016
27028349	Adjuvant Pelvic Radiation TherapyÂ±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.	Am J Clin Oncol	2016
26073941	ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.	Cell	2015
26793763	Clinically aggressive "low-grade" uterine carcinosarcoma: A case report.	Gynecol Oncol Rep	2015
26132572	Inhibition of autophagy in peripheral blood mononuclear cells by vaginal fluid from women with a malignant adnexal mass.	Int J Cancer	2015
26051168	Role of cystathionine Î²-synthase in human breast Cancer.	Free Radic Biol Med	2015
24211482	Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.	Am J Obstet Gynecol	2014
25556268	Clinical outcomes of patients with adenocarcinoma in situ of the cervix treated by conization.	Eur J Gynaecol Oncol	2014
25078343	Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.	Int J Gynecol Cancer	2014
23344410	Unsuccessful planned conservative resection of placental site trophoblastic tumor.	Obstet Gynecol	2013
24475582	Role of surgical staging and adjuvant treatment in uterine serous carcinoma.	Eur J Gynaecol Oncol	2013
24138915	Administration of concurrent vaginal brachytherapy during chemotherapy for treatment of endometrial cancer.	Int J Radiat Oncol Biol Phys	2013
23850276	Lung-conserving treatment of a pulmonary oligometastasis with a wedge resection and 131Cs brachytherapy.	Brachytherapy	2013
23228822	Recurrent skeletal muscle and abdominopelvic low-grade leiomyosarcoma.	Int J Gynaecol Obstet	2013
23162933	Adolescent with an abdominal mass.	Adolesc Med State Art Rev	2012
21396492	Challenges in the clinical management of blood-culture negative endocarditis: case of Bartonella henselae infection.	Am J Med	2011
21768858	Pelvic Salmonella infection masquerading as gynecologic malignancy.	Obstet Gynecol	2011
21341363	Side-docking in robotic-assisted gynaecologic cancer surgery.	Int J Med Robot	2011
21436701	Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma.	Int J Gynecol Cancer	2011
19307014	A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers.	Gynecol Oncol	2009
19236220	The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies.	Expert Opin Drug Saf	2009
18765524	Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer.	Clin Cancer Res	2008
18781912	Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism.	Curr Drug Metab	2008
17034837	Synchronous ovarian granulosa cell tumor and uterine serous carcinoma: a rare association of a high-risk endometrial cancer with anestrogenic ovarian tumor.	Gynecol Oncol	2006

1 - 42 of 42

Yovanni Casablanca

Uniformed Services of the Health Sciences Gynecologic Cancer Center of Excellence

Career Start Year 2007

Number of shared co-authors 1

Shin-Wha Lee

Asan Medical Center, University of Ulsan College of Medicine

Career Start Year 2006

Number of shared co-authors 0

Donal J Brennan

National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital

Career Start Year 2005

Number of shared co-authors 0

Stefan Kommoss

Eberhard Karls University Tubingen

Career Start Year 2005

Number of shared co-authors 2

Susana Banerjee

The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

Career Start Year 2005

Number of shared co-authors 3

Robyn A Sayer

Westmead Hospital

Career Start Year 2003

Number of shared co-authors 2

Maria Del Pilar Estevez Diz

Instituto do Cancer do Estado de Sao Paulo and Universidade de Sao Paulo

Career Start Year 2002

Number of shared co-authors 0

Blaise A Clarke

University of Toronto.

Career Start Year 2001

Number of shared co-authors 1

Douglas A Levine

Perlmutter Cancer Center

Career Start Year 1999

Number of shared co-authors 3

Susan C Modesitt

University of Virginia, Emily Couric Clinical Cancer Center

Career Start Year 1998

Number of shared co-authors 0

Isabelle Ray-Coquard

University Claude Bernard Lyon I

Career Start Year 1997

Number of shared co-authors 3

Kathleen M Schmeler

The University of Texas MD Anderson Cancer Center

Career Start Year 1996

Number of shared co-authors 1

Alison Brand

Westmead Hospital

Career Start Year 1995

Number of shared co-authors 2

Paulette Mhawech-Fauceglia

University of Southern California

Career Start Year 1995

Number of shared co-authors 0

Michael E Carney

John A. Burns School of Medicine, University of Hawaii

Career Start Year 1995

Number of shared co-authors 2

Annette Hasenburg

University Medical Center, Johannes Gutenberg University Mainz

Career Start Year 1994

Number of shared co-authors 1

Yong-Man Kim

Asan Medical Center, University of Ulsan College of Medicine

Career Start Year 1994

Number of shared co-authors 0

Naveena Singh

Barts Health NHS Trust

Career Start Year 1993

Number of shared co-authors 2

Rosalind Glasspool

University of Glasgow

Career Start Year 1992

Number of shared co-authors 2

George L Maxwell

Women's Health Integrated Research Center, Inova Health System

Career Start Year 1992

Number of shared co-authors 1

Anil K Sood

The University of Texas MD Anderson Cancer Center

Career Start Year 1991

Number of shared co-authors 2

Gustavo C Rodriguez

Clinica Quirurgica 2 (Surgical Clinic 2), Hospital Maciel

Career Start Year 1990

Number of shared co-authors 2

Kathleen M Darcy

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

Career Start Year 1990

Number of shared co-authors 1

Fr??d??ric Amant

Netherlands Cancer Institute

Career Start Year 1989

Number of shared co-authors 1

Tanja Pejovic

Oregon Health & Science University

Career Start Year 1989

Number of shared co-authors 2

Cyril B Gilks

University of British Columbia

Career Start Year 1987

Number of shared co-authors 2

Gary L Keeney

Mayo Clinic

Career Start Year 1984

Number of shared co-authors 2

Andrew Berchuck

Duke School of Medicine

Career Start Year 1983

Number of shared co-authors 2

Beth Y Karlan

David Geffen School of Medicine, University of California los angeles

Career Start Year 1981

Number of shared co-authors 2

Anna DeFazio

Westmead Hospital

Career Start Year 1972

Number of shared co-authors 2

row(s) 1 - 30 of 30

Kevin Holcomb

Weill Cornell Medical College

Co-authored papers 12

Lora H Ellenson

Memorial Sloan Kettering Cancer Center

Co-authored papers 5

Cathleen Matrai

Weill Cornell Medical Center

Co-authored papers 3

Himanshu Nagar

New York-Presbyterian Hospital, Weill Cornell Medical Center

Co-authored papers 2

Amanda Golembesky

Co-authored papers 2

Sudeshna Chatterjee

Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health

Co-authored papers 2

Shannon M Glynn

Weill Cornell Medical College

Co-authored papers 1

Boaz Kurtis

Westchester Medical Center

Co-authored papers 1

Eloise Chapman-Davis

Weill Cornell Medical College

Co-authored papers 1

Kenneth Eng

Caryl and Israel Englander Institute for Precision Medicine

Co-authored papers 1

Sven Mahner

University Hospital

Co-authored papers 1

Gottfried E Konecny

David Geffen School of Medicine at University of California Los Angeles

Co-authored papers 1

Shikha Bose

Co-authored papers 1

Olivier Elemento

Meyer Cancer Center

Co-authored papers 1

Pooja Chandra

Weill Cornell Medical College

Co-authored papers 1

Kentaro Ohara

Caryl and Israel Englander Institute for Precision Medicine.

Co-authored papers 1

Sahil Chopra

Loma Linda University

Co-authored papers 1

Kym F Faull

Co-authored papers 1

Mani A Daneshmand

Emory University

Co-authored papers 1

Susanna Mirabelli

Co-authored papers 1

Alexandros Sigaras

Columbia University, United States Bureau of Educational and Cultural Affairs Fulbright Program, University of Piraeus, Weill Cornell Medical College, Weill Cornell Medicine

Co-authored papers 1

Bing He

Liver Cancer Institute, Shanghai Medical University

Co-authored papers 1

Samaneh Motanagh

Dartmouth-Hitchcock Medical Center

Co-authored papers 1

Juan Miguel Mosquera

Caryl and Israel Englander Institute for Precision Medicine

Co-authored papers 1

Zev Rosenwaks

Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine